KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash & Equivalents (2016 - 2025)

Novavax has reported Cash & Equivalents over the past 16 years, most recently at $240.6 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $240.6 million for Q4 2025, down 54.62% from a year ago — trailing twelve months through Dec 2025 was $240.6 million (down 54.62% YoY), and the annual figure for FY2025 was $240.6 million, down 54.62%.
  • Cash & Equivalents for Q4 2025 was $240.6 million at Novavax, down from $268.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for NVAX hit a ceiling of $2.1 billion in Q2 2021 and a floor of $10.3 million in Q2 2022.
  • Median Cash & Equivalents over the past 5 years was $374.3 million (2024), compared with a mean of $587.5 million.
  • Biggest five-year swings in Cash & Equivalents: surged 28820.03% in 2021 and later crashed 99.5% in 2022.
  • Novavax's Cash & Equivalents stood at $1.5 billion in 2021, then crashed by 99.32% to $10.3 million in 2022, then soared by 5417.86% to $568.5 million in 2023, then dropped by 6.73% to $530.2 million in 2024, then tumbled by 54.62% to $240.6 million in 2025.
  • The last three reported values for Cash & Equivalents were $240.6 million (Q4 2025), $268.0 million (Q3 2025), and $253.7 million (Q2 2025) per Business Quant data.